Tina Marriott - 27 Jun 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
President and COO
Signature
/s/Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
27 Jun 2024
Net transactions value
-$36,930
Form type
4
Filing time
28 Jun 2024, 17:14:06 UTC
Previous filing
03 Jun 2024
Next filing
29 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $6,360 +6,000 +1.1% $1.06 541,457 27 Jun 2024 Direct F1
transaction RXRX Class A Common Stock Sale $43,290 -6,000 -1.1% $7.22 535,457 27 Jun 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -6,000 -1.2% $0.000000 476,000 27 Jun 2024 Class A Common Stock 6,000 $1.06 Direct F1, F3
holding RXRX Stock Option (Right to Buy) 434,122 27 Jun 2024 Class A Common Stock 0 $8.55 Direct F4
holding RXRX Stock Option (Right to Buy) 159,226 27 Jun 2024 Class A Common Stock 0 $11.40 Direct F5
holding RXRX Stock Option (Right to Buy) 4,784 27 Jun 2024 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 150,000 27 Jun 2024 Class A Common Stock 0 $2.48 Direct F6
holding RXRX Stock Option (Right to Buy) 447,917 27 Jun 2024 Class A Common Stock 0 $10.09 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $6.91 to $7.575. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
F7 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.